Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
alcohol
Biotech
Durect fails alcohol-associated hepatitis trial, plans phase 3
The biotech hailed “remarkable” results but failed to persuade investors to look past the failure of the primary endpoint, causing its stock to sink.
Nick Paul Taylor
Nov 8, 2023 7:57am
Adial at a fork in the road with AUD med after phase 3 flunk
Jul 20, 2022 10:55am
Abbott unveils Lingo line of sports biosensors
Jan 6, 2022 2:20pm
AASLD: Durect's alcoholic hepatitis med shows early promise
Nov 12, 2019 8:45am
FDA approves mobile app to help treat substance abuse
Sep 14, 2017 3:00pm
